A Dose-Escalation, Safety and Pharmacokinetic Study of SAR3419 Administered as a Single Agent by Intravenous Infusion Once Weekly in Patients With Relapsed/Refractory CD19-Positive B-Cell Non-Hodgkin's Lymphoma (NHL).

Trial Profile

A Dose-Escalation, Safety and Pharmacokinetic Study of SAR3419 Administered as a Single Agent by Intravenous Infusion Once Weekly in Patients With Relapsed/Refractory CD19-Positive B-Cell Non-Hodgkin's Lymphoma (NHL).

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2013

At a glance

  • Drugs Coltuximab ravtansine (Primary)
  • Indications B cell lymphoma
  • Focus Adverse reactions
  • Sponsors Sanofi
  • Most Recent Events

    • 04 Jun 2012 Results from the extension phase of the trial have been presented at the 48th Annual Meeting of the American Society of Oncology (ASCO).
    • 01 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 May 2012 Results will be presented at the 48th Annual Meeting of the American Society of Oncology (ASCO).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top